Roles of TGF‑β signalling pathway‑related lncRNAs in cancer (Review)

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Long non-coding RNAs (lncRNAs) are a class of RNAs that are >200 nucleotides in length that do not have the ability to be translated into protein but are associated with numerous diseases, including cancer. The involvement of lncRNAs in the signalling of certain signalling pathways can promote tumour progression; these pathways include the transforming growth factor (TGF)-β signalling pathway, which is related to tumour development. The expression of lncRNAs in various tumour tissues is specific, and their interaction with the TGF-β signalling pathway indicates that they may serve as new tumour markers and therapeutic targets. The present review summarized the role of TGF-β pathway-associated lncRNAs in regulating tumorigenesis in different types of cancer and their effects on the TGF-β signalling pathway.

Related collections

Most cited references 130

Record: found
Abstract: found
Article: not found

Gastric cancer

Elizabeth Smyth, Magnus Nilsson, Heike I Grabsch … (2020)

Gastric cancer is the fifth most common cancer and the third most common cause of cancer death globally. Risk factors for the condition include Helicobacter pylori infection, age, high salt intake, and diets low in fruit and vegetables. Gastric cancer is diagnosed histologically after endoscopic biopsy and staged using CT, endoscopic ultrasound, PET, and laparoscopy. It is a molecularly and phenotypically highly heterogeneous disease. The main treatment for early gastric cancer is endoscopic resection. Non-early operable gastric cancer is treated with surgery, which should include D2 lymphadenectomy (including lymph node stations in the perigastric mesentery and along the celiac arterial branches). Perioperative or adjuvant chemotherapy improves survival in patients with stage 1B or higher cancers. Advanced gastric cancer is treated with sequential lines of chemotherapy, starting with a platinum and fluoropyrimidine doublet in the first line; median survival is less than 1 year. Targeted therapies licensed to treat gastric cancer include trastuzumab (HER2-positive patients first line), ramucirumab (anti-angiogenic second line), and nivolumab or pembrolizumab (anti-PD-1 third line).

0 comments Cited 2125 times – based on 0 reviews      Review now

Record: found
Abstract: found
Article: not found

A global view of hepatocellular carcinoma: trends, risk, prevention and management

Ju Yang, Pierre Hainaut, Gregory J. Gores … (2019)

Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death worldwide. Risk factors for HCC include chronic hepatitis B and hepatitis C, alcohol addiction, metabolic liver disease (particularly nonalcoholic fatty liver disease) and exposure to dietary toxins such as aflatoxins and aristolochic acid. All these risk factors are potentially preventable, highlighting the considerable potential of risk prevention for decreasing the global burden of HCC. HCC surveillance and early detection increase the chance of potentially curative treatment; however, HCC surveillance is substantially underutilized, even in countries with sufficient medical resources. Early-stage HCC can be treated curatively by local ablation, surgical resection or liver transplantation. Treatment selection depends on tumour characteristics, the severity of underlying liver dysfunction, age, other medical comorbidities, and available medical resources and local expertise. Catheter-based locoregional treatment is used in patients with intermediate-stage cancer. Kinase and immune checkpoint inhibitors have been shown to be effective treatment options in patients with advanced-stage HCC. Together, rational deployment of prevention, attainment of global goals for viral hepatitis eradication, and improvements in HCC surveillance and therapy hold promise for achieving a substantial reduction in the worldwide HCC burden within the next few decades.

0 comments Cited 1838 times – based on 0 reviews      Review now

Record: found
Abstract: found
Article: not found

Long Noncoding RNA and Cancer: A New Paradigm.

Milad Soleimani, Subhrangsu Mandal, Arunoday Bhan (2017)

In addition to mutations or aberrant expression in the protein-coding genes, mutations and misregulation of noncoding RNAs, in particular long noncoding RNAs (lncRNA), appear to play major roles in cancer. Genome-wide association studies of tumor samples have identified a large number of lncRNAs associated with various types of cancer. Alterations in lncRNA expression and their mutations promote tumorigenesis and metastasis. LncRNAs may exhibit tumor-suppressive and -promoting (oncogenic) functions. Because of their genome-wide expression patterns in a variety of tissues and their tissue-specific expression characteristics, lncRNAs hold strong promise as novel biomarkers and therapeutic targets for cancer. In this article, we have reviewed the emerging functions and association of lncRNAs in different types of cancer and discussed their potential implications in cancer diagnosis and therapy. Cancer Res; 77(15); 3965-81. ©2017 AACR.

0 comments Cited 1224 times – based on 0 reviews      Review now

All references

Author and article information

Journal

Journal ID (nlm-ta): Oncol Lett

Journal ID (iso-abbrev): Oncol Lett

Journal ID (publisher-id): OL

Title: Oncology Letters

Publisher: D.A. Spandidos

ISSN (Print): 1792-1074

ISSN (Electronic): 1792-1082

Publication date Collection: March 2023

Publication date (Electronic): 02 February 2023

Publication date PMC-release: 02 February 2023

Volume: 25

Issue: 3

Electronic Location Identifier: 107

Affiliations

Cancer Research Institute, Medical School, University of South China, Hengyang, Hunan 421001, P.R. China

Author notes

Correspondence to: Dr Yang Zhang or Dr Chengkun Wang, Cancer Research Institute, Medical School, University of South China, 28 Chang Sheng Xi Avenue, Hengyang, Hunan 421001, P.R. China, E-mail: charleswzygmail.com yangyang@ 123456usc.edu.cn

[*]

Contributed equally

Article

Publisher ID: OL-25-3-13693

DOI: 10.3892/ol.2023.13693

PMC ID: 9932718

PubMed ID: 36817052

SO-VID: 1fc07cca-d04c-4c5f-8e15-f83e0735c4a5

License:

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

History

Date received : 19 September 2022

Date accepted : 13 January 2023

Funding

Funded by: Youth Program of National Natural Science Foundation of China

Award ID: 81500169

Funded by: Hunan Provincial Groundbreaking Platform Open Fund of University of South China

Award ID: 19K080

Funded by: Student Research Learning and Innovative Experimental Project of the University of South China

Award ID: 20155760439

Award ID: X2019141

The present study was supported by the Youth Program of National Natural Science Foundation of China (grant no. 81500169), the Hunan Provincial Groundbreaking Platform Open Fund of University of South China (grant no. 19K080) and the Student Research Learning and Innovative Experimental Project of the University of South China (grant nos. 20155760439 and X2019141).

Roles of TGF‑β signalling pathway‑related lncRNAs in cancer (Review)

Read this article at

Abstract

Related collections

Karger: Oncology

Most cited references 130

Gastric cancer

A global view of hepatocellular carcinoma: trends, risk, prevention and management

Long Noncoding RNA and Cancer: A New Paradigm.

Author and article information

Journal

Affiliations

Author notes

Article

History

Funding

Categories

Comments

Comment on this article

Similar content 57

Cited by 5

Most referenced authors 1,687